We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance.
- Authors
Noetzli, Jasmine; Gavillet, Mathilde; Masouridi‐Levrat, Stavroula; Duchosal, Michel; Spertini, Olivier
- Abstract
Key Clinical Message We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR-ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib.
- Subjects
LYMPHOBLASTIC leukemia; CLONAL selection theory; PROTEIN-tyrosine kinase inhibitors; DISEASE relapse; GENETIC mutation; PATIENTS
- Publication
Clinical Case Reports, 2017, Vol 5, Issue 8, p1320
- ISSN
2050-0904
- Publication type
Article
- DOI
10.1002/ccr3.1032